Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
China Isotope & Radiation Corp. ( (HK:1763) ) has shared an announcement.
China Isotope & Radiation Corporation has announced a commercial cooperation agreement between its subsidiary HTA Co., Ltd. and Novartis Pharma Technology (Zhejiang) Co., Ltd. This agreement focuses on Pluvicto®, a prostate-specific membrane antigen-targeted radioligand therapy for advanced prostate cancer. The collaboration aims to leverage HTA’s experience in radiopharmaceuticals to supply Pluvicto® and related solutions, enhancing treatment options and improving patient outcomes in the PRC.
The most recent analyst rating on (HK:1763) stock is a Buy with a HK$25.00 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.
More about China Isotope & Radiation Corp.
China Isotope & Radiation Corporation is a company based in the People’s Republic of China, operating in the radiopharmaceuticals industry. It focuses on providing nuclear medicine products and services, with a market emphasis on innovative therapies for medical institutions and patients.
Average Trading Volume: 369,470
Technical Sentiment Signal: Buy
Current Market Cap: HK$6.75B
For detailed information about 1763 stock, go to TipRanks’ Stock Analysis page.